Inc. Recognizes Decode Health as a Top 100 Company in the Southeast

Inc., known for its insightful coverage of innovative businesses and start-up companies, acknowledges the fastest-growing private entities in the United States. Decode Health was recognized as one of Inc.’s top 100 companies of 2024, driving innovation and impact in the Southeastern United States. This annual listing is determined through a competitive review using a series of company metrics.

Decode Health leverages its dynamic, disease-agnostic data platform to advance precision medicine initiatives. Decode’s platform integrates clinical, biological, and social determinants of health information with advanced analytics and machine learning techniques to accelerate biomarker discovery and create new clinical decision support tools in support of pharmaceutical, diagnostic, and other technology companies. These efforts largely focus on new ways to detect, monitor, and predict disease outcomes.

Over the past year, the Decode Health team has presented their work at multiple national and international conferences the joint European and American Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS) event in Milan, Italy. These presentations highlighted the use of Decode’s platform to identify new RNA biomarkers to better diagnose, subtype, and treat neurodegenerative diseases, including multiple sclerosis and neuromyelitis optica. Decode’s data platform and partner ecosystem enable advanced analysis and biomarker discovery opportunities, utilizing an end-to-end framework for data access, data asset creation, and rigorous quality control metrics to ensure accuracy and scalability.

For more details, visit Inc.com